Reimagining Medicine Q2 2023 Results

Company overview Innovation: Pipeline overview Financial review Financial performance Conclusions Our pipeline projects at a glance Innovative medicines Solid Tumors Hematology Immunology Neuroscience Cardiovascular Others Ophthalmology Respiratory & Allergy IB&GH Biosimilars¹ Appendix Innovation: Clinical trials References Abbreviations Phase 1/2 Phase 3 Registration Total 78 44 7 129 14 12 2 28 18 7 1 26 20 10 4 34 6 5 0 11 15 82 553 0 13 0 17 1 0 4 3 0 0 3 9 1 0 10 n/a 2 0 2 Total 78 46 7 131 1. Selected disclosed, internal projects. Biosimilar pre-Phase 3 are not disclosed. 31 Investor Relations | Q2 2023 Results INNOVATION 1 NOVARTIS | Reimagining Medicine

View entire presentation